Here's some news.
The FDA has awarded a failed Alzheimers drug from Roche breakthrough therapy designation 10 years after it was rejected after failing trials.
It hit some amyloid targets but was tossed after failing common test standards.
Perhaps they could review the canine standard for PBT2
Experimental method to study macula degeneration, page-5
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(12.5%) |
Mkt cap ! $23.94M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $508 | 124.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 103 | 97947018 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 31179262 | 15 |
View Market Depth
| Last trade - 11.42am 25/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |